Table 1. Characteristics and quality assessment of 48 studies included in meta-analysis.
| First author | Year | Country | Ethnicity | Patients (controls) |
Cancer | Sample | method | ECon | Sen | Spe | Tp | Fp | Fn | Tn | AUC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wei J[23] | 2011 | China | Asian | 77(36) | LC | Plasma | SYBR | miR-16 | 61.04 | 83.33 | 47 | 6 | 30 | 30 | 0.729 |
| Shen J[24] | 2011 | USA | Caucasian African | 58(29) | LC | Plasma | SYBR | miR-16 | 79.31 | 65.52 | 46 | 10 | 12 | 19 | 0.816 |
| Li Y[25] | 2011 | China | Asian | 20(10) | LC | Serum | SYBR | mimics | 78.80 | 100.00 | 16 | 0 | 4 | 10 | 0.912 |
| Le HB[26] | 2012 | China | Asian | 82(50) | LC | Serum | Taqman | miR-16 | 46.30 | 92.00 | 38 | 4 | 44 | 46 | 0.686 |
| Wang B[9] | 2012 | China | Asian | 31(39) | LC | Serum | SYBR | miR-16 | 87.10 | 74.40 | 27 | 10 | 4 | 29 | 0.880 |
| Tang D[27] | 2013 | China | Asian | 62(60) | LC | Plasma | Taqman | RNU6 | 48.40 | 78.30 | 30 | 13 | 32 | 47 | 0.715 |
| Tang D[27] | 2013 | China | Asian | 34(32) | LC | Plasma | Taqman | RNU6 | 52.90 | 71.90 | 18 | 9 | 16 | 23 | 0.709 |
| Abd-EI-Fattah AA[28] | 2013 | Egypt | African | 65(37) | LC | Serum | SYBR | RNU48 | 85.70 | 86.50 | 56 | 5 | 9 | 32 | 0.850 |
| Mozzoni P[29] | 2013 | Italy | Caucasian | 54(46) | LC | Plasma | Taqman | miR-16 | 50.00 | 92.30 | 27 | 4 | 27 | 42 | 0.740 |
| Yang JS[56] | 2014 | China | Asian | 300(152) | LC | Serum | Taqman | RNU6 | 69.00 | 71.00 | 207 | 45 | 93 | 107 | 0.810 |
| Kanaan Z[57] | 2012 | USA | Caucasian | 50(50) | CC | Plasma | Taqman | RNU6 | 90.00 | 90.00 | 45 | 5 | 5 | 45 | 0.820 |
| Wang B[9] | 2012 | China | Asian | 32(39) | CC | Serum | SYBR | miR-16 | 87.50 | 74.40 | 28 | 10 | 4 | 29 | 0.850 |
| Toiyama Y[30] | 2013 | Japan | Asian | 186(53) | CC | Serum | Taqman | cel-miR-39 | 82.80 | 90.60 | 154 | 5 | 32 | 48 | 0.919 |
| Liu GH[31] | 2013 | China | Asian | 200(80) | CC | Serum | Taqman | miR-16 | 65.00 | 85.00 | 130 | 12 | 70 | 68 | 0.802 |
| Luo X[32] | 2013 | Germany | Caucasian | 80(144) | CC | Plasma | Taqman | miR-16 | 51.70 | 80.70 | 41 | 28 | 39 | 116 | 0.653 |
| Basati G[33] | 2014 | Iran | Caucasian | 40(40) | CC | Serum | SYBR | RNU6 | 77.00 | 78.00 | 31 | 9 | 9 | 31 | 0.870 |
| Ogata-kawata H[34] | 2014 | Japan | Asian | 88(11) | CC | Serum | Taqman | miR-451 | 61.40 | 90.90 | 54 | 1 | 34 | 10 | 0.798 |
| Tsujiura M[35] | 2010 | Japan | Asian | 69(30) | GC | Plasma | Taqman | RNU6 | 60.90 | 63.33 | 42 | 11 | 27 | 19 | 0.673 |
| Zheng Y[36] | 2011 | China | Asian | 53(20) | GC | Plasma | SYBR | RNU6 | 83.77 | 80.53 | 44 | 4 | 9 | 16 | 0.853 |
| Li BS[37] | 2012 | China | Asian | 60(60) | GC | Plasma | Taqman | cel-miR-39 | 74.29 | 75.71 | 45 | 15 | 15 | 45 | 0.794 |
| Wang B[9] | 2012 | China | Asian | 30(39) | GC | Serum | SYBR | miR-16 | 56.70 | 94.90 | 17 | 2 | 13 | 37 | 0.810 |
| Shiotani A[38] | 2013 | Japan | Asian | 64(64) | GC | Serum | Taqman | miR-16 | 58.60 | 86.10 | 38 | 9 | 26 | 55 | 0.720 |
| Wu J[22] | 2015 | China | Asian | 50(50) | GC | Serum | SYBR | RNU6 | 83.77 | 79.60 | 44 | 10 | 6 | 40 | 0.912 |
| Wu J[22] | 2015 | China | Asian | 50(50) | GC | PBMC | SYBR | RNU6 | 74.29 | 73.40 | 41 | 13 | 9 | 37 | 0.898 |
| Xu J[39] | 2011 | China | Asian | 101(89) | HCC | Serum | SYBR | miR-181 | 56.70 | 73.50 | 85 | 24 | 16 | 65 | 0.870 |
| Tomimaru Y[40] | 2012 | Japan | Asian | 126(50) | HCC | Plasma | Taqman | miR-16 | 87.30 | 92.00 | 110 | 4 | 16 | 46 | 0.953 |
| Tomimaru Y[40] | 2012 | Japan | Asian | 126(30) | HCC | Plasma | Taqman | miR-16 | 61.10 | 83.30 | 77 | 5 | 49 | 25 | 0.773 |
| Liu AM[41] | 2012 | China | Asian | 57(59) | HCC | Serum | Taqman | NA | 89.47 | 71.19 | 51 | 17 | 6 | 42 | 0.865 |
| Amr KS[42] | 2015 | Egypt | African | 23(17) | HCC | Serum | Taqman | RNU48 | 100.00 | 81.20 | 23 | 3 | 0 | 14 | 0.943 |
| Zhuang C[59] | 2015 | China | Asian | 52(43) | HCC | Serum | SYBR | cel-miR-39 RNU6 |
67.40 | 55.80 | 35 | 19 | 17 | 24 | 0.621 |
| Asaga S[43] | 2011 | USA | Caucasian | 79(20) | BC | Serum | SYBR | miR-16 | 67.00 | 75.00 | 53 | 5 | 26 | 15 | 0.721 |
| Wang B[9] | 2012 | China | Asian | 50(39) | BC | Serum | SYBR | miR-16 | 80.00 | 87.70 | 40 | 5 | 10 | 34 | 0.880 |
| Mar-Aguilar F[44] | 2013 | Mexico | Caucasian | 60(10) | BC | Serum | Taqman | 18s RNA | 94.40 | 80.00 | 57 | 2 | 3 | 8 | 0.950 |
| Gao J[45] | 2013 | China | Asian | 89(55) | BC | Serum | SYBR | miR-16 | 87.60 | 87.30 | 78 | 7 | 11 | 48 | 0.929 |
| Toraih EA[46] | 2015 | Egypt | African | 30(60) | BC | Serum | Taqman | RNU6 | 66.70 | 86.70 | 20 | 8 | 10 | 52 | 0.800 |
| Motawi TM[58] | 2016 | Egypt | African | 50(25) | BC | Serum | SYBR | RNU48 | 96.00 | 92.00 | 48 | 2 | 2 | 23 | 0.984 |
| Motawi TM[58] | 2016 | Egypt | African | 50(25) | BC | Serum | SYBR | RNU48 | 82.00 | 76.00 | 41 | 6 | 9 | 19 | 0.855 |
| Kurashige J[47] | 2012 | Japan | Asian | 71(39) | EC | Serum | Taqman | miR-16 | 46.50 | 100.00 | 33 | 0 | 38 | 39 | NA |
| Wang B[9] | 2012 | China | Asian | 31(39) | EC | Serum | SYBR | miR-16 | 71.00 | 69.20 | 22 | 12 | 9 | 27 | 0.740 |
| Wang J[48] | 2009 | USA | Caucasian | 49(36) | PC | Plasma | Taqman | miR-16 | 46.00 | 89.00 | 23 | 4 | 26 | 32 | 0.620 |
| Hsu CM[49] | 2012 | China | Asian | 50(36) | HNSCC | Plasma | Taqman | cel-miR-39 | 83.30 | 51.10 | 42 | 18 | 8 | 18 | 0.741 |
| Liu X[50] | 2013 | China | Asian | 217(73) | NPC | Plasma | SYBR | RNU6 | 76.00 | 69.90 | 165 | 22 | 52 | 51 | 0.792 |
| Kishimoto T[51] | 2013 | Japan | Asian | 94(50) | BTC | Plasma | Taqman | miR-16 | 85.10 | 100.00 | 80 | 0 | 14 | 50 | 0.930 |
| Kishimoto T[51] | 2013 | Japan | Asian | 94(23) | BTC | Plasma | Taqman | miR-16 | 72.30 | 91.30 | 68 | 2 | 26 | 21 | 0.830 |
| Jones K[52] | 2014 | Australia | Caucasian | 42(20) | Lym | Plasma | SYBR | cel-miR-39 | 95.00 | 86.00 | 40 | 3 | 2 | 17 | 0.920 |
| Wang J[53] | 2014 | China | Asian | 52(49) | LSCC | Serum | SYBR | RNU6 | 69.20 | 81.60 | 36 | 9 | 16 | 40 | 0.801 |
| Huang W[54] | 2015 | China | Asian | 75(75) | PCa | PBMC | Taqman | RNU6 | 87.50 | 85.70 | 66 | 11 | 9 | 64 | 0.833 |
| Liu SS[55] | 2014 | China | Asian | 65(65) | RB | Plasma | SYBR | RNU6 | 46.00 | 72.00 | 30 | 18 | 35 | 47 | 0.548 |
Sen: sensitivity, Spe: specificity, Econ: endogenous control, Tp: true positive, Fp: false positive, Fn: false negative, Tn: true negative, AUC: area under ROC curve, LC: lung cancer, CC: colorectal cancer, GC: gastric cancer, HHC: hepatocellular cancer, BC: breast cancer, EC: esophageal cancer, PC: pancreatic cancer, HNSCC: head and neck squamous cell cancer, NPC: nasopharyngeal cancer, BTC: biliary tract cancer, Lym: Lymphoma, LSCC: laryngeal squamous cell cancer, PCa: prostate cancer, RB: retinoblastoma, PBMC: peripheral blood mononuclear cell, NA: not available